Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394641 | 1.00 | LRRK2 (0.57) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL396629 | 0.90 | LRRK2 (0.70) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL396628 | 0.90 | LRRK2 (0.70) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL398034 | 0.85 | L3MBTL3 (0.53) | LRRK2L3MBTL1L3MBTL3ALDH1A1MEN1 | |
| SCHEMBL398033 | 0.85 | L3MBTL3 (0.53) | LRRK2L3MBTL1L3MBTL3ALDH1A1MEN1 | |
| SCHEMBL399814 | 0.85 | CACNA1H (0.54) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL399815 | 0.85 | CACNA1H (0.54) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL15131501 | 0.82 | L3MBTL3 (0.65) | L3MBTL1L3MBTL3ALDH1A1KDM4EMEN1 | |
| SCHEMBL18407314 | 0.80 | ALDH1A1 (0.60) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E | |
| SCHEMBL16982454 | 0.80 | ALDH1A1 (0.60) | LRRK2L3MBTL1L3MBTL3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210827-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | LRRK2 940/4885L3MBTL1 1498/4885L3MBTL3 2063/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | LRRK2 940/4885L3MBTL1 1498/4885L3MBTL3 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.